Constellation Pharmaceuticals Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Optio...
13 Décembre 2019 - 10:05PM
Constellation Pharmaceuticals, Inc., (Nasdaq: CNST) a
clinical-stage biopharmaceutical company using its expertise in
epigenetics to discover and develop novel therapeutics, today
announced closing of its previously announced underwritten public
offering of 7,475,000 shares of its common stock at a public
offering price of $34.50 per share, which includes 975,000 shares
issued upon the exercise in full by the underwriters of their
option to purchase additional shares at the public offering price,
less underwriting discounts and commissions. The total gross
proceeds of the offering were $257.9 million, before deducting
underwriting discounts and commissions and expenses payable by
Constellation. All of the shares in the offering are being sold by
Constellation.
J.P. Morgan, Jefferies and Cowen acted as joint book-running
managers for the offering. RBC Capital Markets acted as a
bookrunner, and SunTrust Robinson Humphrey acted as lead manager
for the offering.
The shares were offered by Constellation pursuant to an
automatically effective shelf registration statement that was
previously filed with the Securities and Exchange Commission
(“SEC”) on December 9, 2019.
This offering was made only by means of a prospectus and
prospectus supplement that form a part of the registration
statement. A final prospectus supplement relating to and describing
the terms of the offering has been filed with the SEC and is
available on the SEC’s website at www.sec.gov. Copies of the final
prospectus supplement and the accompanying prospectus may also be
obtained by contacting: J.P. Morgan Securities LLC, c/o Broadridge
Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717,
telephone: (866) 803-9204; Jefferies LLC, Attention: Equity
Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New
York, NY 10022, by telephone at 877-821-7388 or by email at
Prospectus_Department@Jefferies.com; or Cowen and Company, LLC, c/o
Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood,
NY 11717, Attn: Prospectus Department, by email at
PostSaleManualRequests@broadridge.com or by telephone at (833)
297-2926.
This press release shall not constitute an offer to sell, or a
solicitation of an offer to buy these securities, nor shall there
be any sale of, these securities in any state or jurisdiction in
which such offer, solicitation or sale would be unlawful prior to
registration or qualification under the securities laws of any such
state or jurisdiction.
About Constellation Pharmaceuticals
Constellation Pharmaceuticals is a clinical-stage
biopharmaceutical company developing novel therapeutics that
selectively modulate gene expression to address serious unmet
medical needs in patients with cancer. The Company has a deep
understanding of how epigenetic and chromatin modifications in
cancer cells and in the tumor and immune microenvironment play a
fundamental role in driving disease progression and drug
resistance. Constellation is driving development of the BET
inhibitor CPI-0610 for the treatment of myelofibrosis as well as
the EZH2 inhibitors CPI-1205 and CPI-0209 for the treatment of
metastatic castration-resistant prostate cancer and other cancers.
The Company is also applying its broad research and development
capabilities to explore other novel targets that directly and
indirectly impact gene expression to fuel a sustainable pipeline of
innovative small-molecule product candidates.
ContactsRonald Aldridge Senior Director,
Investor RelationsConstellation Pharmaceuticals+1
617-714-0539ron.aldridge@constellationpharma.com
Lauren ArnoldMedia RelationsMacDougall Biomedical
Communications+1 781-235-3060larnold@macbiocom.com
Constellation Pharmaceut... (NASDAQ:CNST)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024
Constellation Pharmaceut... (NASDAQ:CNST)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024